Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19:336-347. ...
Nauck, M.A. 2017. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19:336-347....
[63] Pathak, V., Gault, V.A., Flatt, P.R., Irwin, N. 2015. Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice. Mol Cell Endocrinol 401:120- 129. [64] ...
[22]Sonne, D.P., Engstrom, T., Treiman, M. 2008. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243-249. [23]Wang, S.X., Xie, Y., Zhou, X., Sha, W.W., Wang, W.L., Han, L.P.,...
[22] Sonne, D.P., Engstrom, T., Treiman, M. 2008. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146:243-249. [23] Wang, S.X., Xie, Y., Zhou, X., Sha, W.W., Wang, W.L., Han, L....
自GLP-1被发现以来,已然成为一种“多面手”激素——其接二连三的代谢功能被人们发现,远远超出了作为肠促胰素的经典定义。
Neumiller JJ: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009, 49 (Suppl 1) : S16-S29.Nobuya, InagakiHitoshi, OnouchiHiroki, SanoNobuo, FunaoShingo, KurodaKohei, Kaku. (2014) SYR-472...
The exact mechanism of action to induce β-cell proliferation is not well understood. Here, using a β-cell specific epidermal growth factor receptor (EGFR) null mouse, we show that exendin-4 induced an increase in proliferation and β-cell mass through EGFR. Thus, our study sheds light on...
some GLP-1 RAs have particularly weak effects with respect to body weight (e.g., albiglutide), whereas other compounds seem to have more pronounced effects (e.g., semaglutide) even if their glucose-lowering effects are similar, has sparked interest in characterizing the mechanism of action. It...
GLP‐1 analoguestype 2 diabetesweight lossThis study aimed to observe the effect of the novel combination of dual add-on therapy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on glycaemic control and weight in patients with...